UMIN ID: UMIN000036420
Registered date:05/04/2019
Novel DCB for Coronary Artery Disease Trial
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Coronary Artery Disease |
| Date of first enrollment | 2019/04/08 |
| Target sample size | 220 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Up to 3 pcs for 1 patient |
Outcome(s)
| Primary Outcome | MACE 12 Months |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | - Female during pregnancy - Patients with creatinine level over 2.0mg/dl - Patients with liver dysfunction - Patients under evaluation for other clinical trials |
Related Information
| Primary Sponsor | Zeon Medical Inc. Business Development Depertment |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Zeon Medical Inc. Business Development Depertment |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Yusuke Oishi |
| Address | Shin Marunouchi Center Bldg, 1-6-2 Marunouchi, Chiyoda-ku, Tokyo Japan 1000005 |
| Telephone | 03-3216-1267 |
| Y.Oishi@zeon.co.jp | |
| Affiliation | Zeon Medical Inc. Business Development Department |
| scientific contact | |
| Name | Norikazu Iwamoto |
| Address | Shin Marunouchi Center Bldg, 1-6-2 Marunouchi, Chiyoda-ku, Tokyo Japan |
| Telephone | 03-3216-1267 |
| N2.Iwamoto@zeon.co.jp | |
| Affiliation | Zeon Medical Inc. Business Development Department |